

PROVIDER QUICK POINTS

PROVIDER INFORMATION



November 9, 2022

MHCP Pharmacy Benefit Exclusion for Pedmark®, Rolvedon™, Skysona®, Spevigo®, and Xenpozyme™

Effective **November 9, 2022**, the drugs listed in the table below are excluded from pharmacy benefit coverage due to clinician-administered route of administration and may be available for medical benefit coverage for subscribers who are eligible.

Drug Names
Pedmark® (sodium thiosulfate injection) solution for intravenous (IV) infusion
Rolvedon™ (eflapegrastim-xnst) solution for subcutaneous use
Skysona® (elivaldogene autotemcel) suspension for intravenous (IV) infusion
Spevigo® (spesolimab-sbzo) solution for intravenous (IV) infusion
Xenpozyme™ (olipudase alfa-rpcp) lyophilized powder for reconstitution for intravenous (IV) infusion

Products Impacted

These exclusions apply to Minnesota Health Care Programs:

- Families and Children [*formerly known as* Prepaid Medical Assistance Program (PMAP)]
- MinnesotaCare (MNCare)
- Minnesota Senior Care Plus (MSC+)

Questions?

If you have questions for a member enrolled in a Minnesota Health Care Programs (MHCP) plan, please contact provider services at **1-866-518-8448**. For all other questions, contact provider services at **(651) 662-5200** or **1-800-262-0820**.

QP93-22

Distribution: bluecrossmn.com/providers/forms-and-publications